Revolution Medicines (RVMD) Non Operating Income (2019 - 2026)

Revolution Medicines' Non Operating Income history runs 8 years deep, the most recent figure standing at -$8.6 million for Q1 2026.

• In Q1 2026, Non Operating Income fell 131.43% year-over-year to -$8.6 million; the TTM figure through Mar 2026 stood at $15.1 million (down 83.4% YoY), while the FY2025 annual figure was $51.1 million, down 42.41% from the prior year.
• Non Operating Income for Q1 2026 stood at -$8.6 million, down from -$3.3 million in the prior quarter.
• The five-year high for Non Operating Income was $27.3 million in Q1 2025, with the low at -$8.6 million in Q1 2026.
• The 5-year median for Non Operating Income is $10.5 million (2023), against an average of $11.0 million.
• The sharpest annual moves came in 2023 and 2026: Non Operating Income jumped 2237.42% in 2023, then sank 131.43% in 2026.
• Revolution Medicines' Non Operating Income stood at $5.1 million in 2022, then jumped by 270.08% to $18.8 million in 2023, then gained by 11.7% to $21.0 million in 2024, then sank by 115.56% to -$3.3 million in 2025, then slumped by 163.14% to -$8.6 million in 2026.
• Business Quant data shows RVMD's Non Operating Income at -$8.6 million in Q1 2026, -$3.3 million in Q4 2025, and $10.1 million in Q3 2025.